Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$14.8m

Quince Therapeutics Management

Management criteria checks 3/4

Quince Therapeutics' CEO is Dirk Thye, appointed in May 2022, has a tenure of 4.08 years. total yearly compensation is $2.49M, comprised of 22.1% salary and 77.9% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $90.53K. The average tenure of the management team and the board of directors is 2.7 years and 7 years respectively.

Key information

Dirk Thye

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage22.06%
CEO tenure4.1yrs
CEO ownership0.6%
Management average tenure2.7yrs
Board average tenure7yrs

Recent management updates

Recent updates

Analysis Article • Jan 21

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Seeking Alpha • Jan 12

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Summary Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment. QNCX has sufficient cash through the NEAT readout, plans for platform expansion, and has a commercialization partnership with Option Care Health. Read the full article on Seeking Alpha
Analysis Article • Oct 07

Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 20

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Summary Quince’s transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel’s earlier trial. Chances for success are high, with approval and multi-billion dollar potential around the corner after topline data next year. The company’s current market cap represents less than half the company’s cash level. Read the full article on Seeking Alpha
Analysis Article • Nov 21

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 27

Cortexyme to change name and ticker symbol next month

Alzheimer’s drug developer Cortexyme (NASDAQ:CRTX) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August. Accordingly, Cortexyme (CRTX) will be branded as Quince Therapeutics next month, and its ticker symbol on the Nasdaq Global Select Market will change to “QNCX” at the market open on Aug. 01. Coinciding with the change, Quince Therapeutics is expected to issue a press release detailing its growth strategy and plans for the development pipeline. In addition, Quince’s new corporate website and social media profiles on Twitter and LinkedIn will launch on the same day. Seeking Alpha contributor Terry Chrisomalis points out that San Francisco, California-based biotech is pursuing a market opportunity worth $17.7B with its Alzheimer's candidate COR588.
Seeking Alpha • Mar 01

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. COR388, the first-generation lysine gingipain inhibitor, didn't achieve statistical significance in the entire Alzheimer's population, but did well in a prespecified group of patients with P. gingivalis. The global market opportunity for Alzheimer's Disease could reach $17.7 billion by 2025. COR388 is not being used towards Alzheimer's Disease, but Cortexyme is still developing it against other P. gingivalis diseases like periodontal disease and oral/head and neck squamous cell carcinoma.

CEO Compensation Analysis

How has Dirk Thye's remuneration changed compared to Quince Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$33m

Dec 31 2025US$2mUS$550k

-US$84m

Sep 30 2025n/an/a

-US$57m

Jun 30 2025n/an/a

-US$49m

Mar 31 2025n/an/a

-US$61m

Dec 31 2024US$3mUS$550k

-US$57m

Sep 30 2024n/an/a

-US$53m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$1mUS$550k

-US$31m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$5mUS$317k

-US$52m

Compensation vs Market: Dirk's total compensation ($USD2.49M) is above average for companies of similar size in the US market ($USD647.55K).

Compensation vs Earnings: Dirk's compensation has been consistent with company performance over the past year.

CEO

Dirk Thye (56 yo)

4.1yrs
Tenure
US$2,493,625
Compensation

Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Dirk Thye
CEO, Chief Medical Officer & Director4.1yrsUS$2.49m0.61%
$ 90.5k
Charles Ryan
President2.8yrsUS$1.14m0.080%
$ 11.8k
Brendan Hannah
Chief Business Officer3.3yrsUS$1.26m0.22%
$ 32.9k
Giovanni Mambrini
Chief Technology Officer2.7yrsno datano data
Guenter Janhofer
Chief Scientific Officer2.7yrsno datano data
Brigette Roberts
Chief Corporate Affairs Officer & Directorless than a yearno datano data
2.7yrs
Average Tenure
53.5yo
Average Age

Experienced Management: QNCX's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dirk Thye
CEO, Chief Medical Officer & Director4.1yrsUS$2.49m0.61%
$ 90.5k
Brigette Roberts
Chief Corporate Affairs Officer & Directorless than a yearno datano data
Ilan Zipkin
Member of Scientific Advisory Boardno dataUS$44.84kno data
Jeffrey Cummings
Member of Clinical Advisory Board7yrsno datano data
Martin Farlow
Member of Clinical Advisory Boardno datano datano data
David Lamond
Independent Chairman of the board10.5yrsUS$98.06k2.69%
$ 399.0k
Pierre Tariot
Member of Clinical Advisory Board7yrsno datano data
Christopher Senner
Independent Director7.3yrsUS$78.98kno data
Mark Brody
Member of Clinical Advisory Boardno datano datano data
David Munoz
Member of Clinical Advisory Boardno datano datano data
Mark Ryder
Member of Clinical Advisory Boardno datano datano data
Mathew Bogyo
Member of Scientific Advisory Boardno datano datano data
7.0yrs
Average Tenure
56yo
Average Age

Experienced Board: QNCX's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 16:20
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quince Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity